Palatin Technologies, Inc.

About Palatin Technologies, Inc.

Palatin Technologies is a biopharmaceutical company focused on discovering and developing novel therapeutics for patients with inflammatory and autoimmune conditions. They leverage the melanocortin system to design treatments that resolve harmful inflammation, providing a unique approach to allow affected tissues to heal.

Products & Services

VYLEESI (bremelanotide injection):A treatment offered by Palatin Technologies, with more information available on their dedicated website.

Pipeline Treatments:Focused on developing treatments for inflammatory and autoimmune diseases, starting with ocular conditions.

Specialties

Melanocortin system Inflammatory and autoimmune conditions Ocular conditions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 18200000 MR: - FA: $18.2 million FAN: 18200000	D: 2025-11-12 FD: 2025-11-12	3 investors
2	RT: Public Offering T: - FT: Public Offering	A: 15800000 MR: - FA: $15.8 million FAN: 15800000	D: 2025-11-06 FD: 2025-11-06	5 investors
3	RT: Public Offering T: - FT: Public Offering	A: 1100000 MR: - FA: approximately $1.1 million FAN: 1100000	D: 2025-05-08 FD: 2025-05-08	3 investors
4	RT: Public Offering T: - FT: Public Offering	A: 11500000 MR: - FA: $11.5 million FAN: 11500000	D: 2025-05-07 FD: 2025-05-07	-
5	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 4700000 MR: - FA: $4.7 million FAN: 4700000	D: 2025-02-07 FD: 2025-02-07	1 investors
6	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 3400000 MR: - FA: approximately $3.4 million FAN: 3400000	D: 2024-12-16 FD: 2024-12-16	1 investors
7	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 6100000 MR: - FA: approximately $6.1 million FAN: 6100000	D: 2024-06-21 FD: 2024-06-21	1 investors
8	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 10000000 MR: - FA: approximately $10 million FAN: 10000000	D: 2024-02-01 FD: 2024-02-01	-
9	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 10000000 MR: - FA: approximately $10 million FAN: 10000000	D: 2024-01-30 FD: 2024-01-30	1 investors
10	RT: Non-dilutive T: - FT: Non-dilutive	A: 4700000 MR: - FA: 4.7 million FAN: 4700000	D: 2023-01-18 FD: 2023-01-18	-

Public Offering Latest

2025-11-12

$18.2M

3 investors (Pro only)

Public Offering 2025-11-06

$15.8M

Public Offering 2025-05-08

$1.1M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Carl Spana

Chief Executive Officer, President, and Director

S

Stephen T. Wills

Chief Financial Officer, Chief Operating Officer, and Treasurer and Secretary

S

Stephen Slusher

Chief Legal Officer

M

Michael Raizman

Chief Medical Officer

J

John Dodd

Senior Vice President, Preclinical Development

J

James Hattersley

Senior Vice President, Business Development

View 12 more team members with Pro

Unlock Full Team Directory

Recent News